Leukemia

New assay will help diagnose, monitor therapy for cancer patients

Published in Cancer Weekly, December 30th, 2003

At the American Society of Hematology meeting in San Diego, California, Cancer Genetics, Inc., (CGI) launched a new, highly sensitive DNA FISH assay to help diagnose and monitor therapy of chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL).

This assay is the first "repeat-free" BCR/ABL four color fluorescent in situ hybridization (F-FISH) probe and it is CGI's first product to be introduced into the United States.

This F-FISH platform is used to simultaneously detect the t(9;22)(q34.1;q11.2) translocations, associated deletions, variants, and amplifications which occur in CML. The assay design improves sensitivity and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-12-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry